Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor

The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nina A. Petunina, Anna L. Terekhova, Ekaterina V. Goncharova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	sglt-2 inhibitors canagliflozin sitagliptin health related quality of life (hrqol) impact of weight on quality of life-lite (iwqol-lite) current health satisfaction questionnaire (ches-q) Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/fb4b48718f144cf18d9defcf7341b996
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb4b48718f144cf18d9defcf7341b996
record_format	dspace
spelling	oai:doaj.org-article:fb4b48718f144cf18d9defcf7341b9962021-11-14T09:00:20ZComparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor2072-03512072-037810.14341/DM7949https://doaj.org/article/fb4b48718f144cf18d9defcf7341b9962016-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7949https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.Nina A. PetuninaAnna L. TerekhovaEkaterina V. GoncharovaEndocrinology Research Centrearticlesglt-2 inhibitorscanagliflozinsitagliptinhealth related quality of life (hrqol)impact of weight on quality of life-lite (iwqol-lite)current health satisfaction questionnaire (ches-q)Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 6, Pp 511-517 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	sglt-2 inhibitors canagliflozin sitagliptin health related quality of life (hrqol) impact of weight on quality of life-lite (iwqol-lite) current health satisfaction questionnaire (ches-q) Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	sglt-2 inhibitors canagliflozin sitagliptin health related quality of life (hrqol) impact of weight on quality of life-lite (iwqol-lite) current health satisfaction questionnaire (ches-q) Nutritional diseases. Deficiency diseases RC620-627 Nina A. Petunina Anna L. Terekhova Ekaterina V. Goncharova Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
description	The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.
format	article
author	Nina A. Petunina Anna L. Terekhova Ekaterina V. Goncharova
author_facet	Nina A. Petunina Anna L. Terekhova Ekaterina V. Goncharova
author_sort	Nina A. Petunina
title	Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
title_short	Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
title_full	Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
title_fullStr	Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
title_full_unstemmed	Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
title_sort	comparative analysis of quality of life in patients treated with canagliflozine or dpp-iv inhibitor
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/fb4b48718f144cf18d9defcf7341b996
work_keys_str_mv	AT ninaapetunina comparativeanalysisofqualityoflifeinpatientstreatedwithcanagliflozineordppivinhibitor AT annalterekhova comparativeanalysisofqualityoflifeinpatientstreatedwithcanagliflozineordppivinhibitor AT ekaterinavgoncharova comparativeanalysisofqualityoflifeinpatientstreatedwithcanagliflozineordppivinhibitor
_version_	1718429566493523968

Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor

Ejemplares similares